Company profile: Nutcracker Therapeutics
1.1 - Company Overview
Company description
- Provider of mRNA therapeutics and an integrated RNA manufacturing platform: the Nutcracker Manufacturing Unit (NMU) for rapid mRNA production from DNA sequences; GMP-in-a-box to lower costs and cycle times; CodonCracker software to optimize RNA sequences; Nutshell delivery vehicles; an RNA therapeutics pipeline across HPV-driven tumors, T cell lymphoma, and genitourinary tumors; and strategic collaborations.
Products and services
- GMP-in-a-box: A scalable approach to RNA manufacturing that reduces costs and cycle times, enabling efficient production of mRNA therapies
- Nutcracker Manufacturing Unit (NMU): A compact device that compresses an entire RNA manufacturing facility into one unit, enabling rapid production of mRNA therapies directly from DNA sequences
- Nutshell delivery vehicles: A nanoparticle-based library for delivering RNA therapeutics, featuring peptoids for enhanced activity and reduced toxicity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nutcracker Therapeutics
Automated Lab Solutions
HQ: Germany
Website
- Description: Provider of life science robotics and automation, including the CellCelector automated system for fluorescence imaging, selection, and image-based sorting/picking of single cells, clusters, adherent cell colonies, and clones from semi-solid media; rare single cell isolation; single cell cloning; stem cell picking; the Incubator FlowBox laminar flow cabinet; and automation components.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Automated Lab Solutions company profile →
Selecta Biosciences
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology focused on overcoming immunogenicity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selecta Biosciences company profile →
Decipher Bio
HQ: United States
Website
- Description: Provider of genomic tests for urological cancers, including Decipher Prostate for risk scores to guide treatment decisions and Decipher Bladder for molecular subtyping to aid planning, and the Decipher GRID research platform of whole-transcriptome profiles. Continues to build its GRID database and partners with pharmaceutical companies to identify biomarkers of response to novel therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Decipher Bio company profile →
Modis Therapeutics
HQ: United States
Website
- Description: Provider of disease-modifying therapies to patients with rare genetic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modis Therapeutics company profile →
Caribou Biosciences
HQ: United States
Website
- Description: Provider of CRISPR genome-editing technologies and allogeneic CAR-T cell therapies for oncology. Offers chRDNA to enhance precision and reduce off-target effects; off-the-shelf CAR-T therapies for hematologic malignancies and autoimmune diseases; and candidates CB-010 (anti-CD19 for B cell non-Hodgkin lymphoma), CB-011 (anti-BCMA for multiple myeloma), and CB-012 (anti-CLL-1 for acute myeloid leukemia).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Caribou Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nutcracker Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nutcracker Therapeutics
2.2 - Growth funds investing in similar companies to Nutcracker Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nutcracker Therapeutics
4.2 - Public trading comparable groups for Nutcracker Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →